Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00069
|
|||||
| Drug Name |
Cabergoline
|
|||||
| Synonyms |
(8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; CG-101; Cabaser; Cabaser (TN); Cabaseril; Cabergolina; Cabergolina [Spanish]; Cabergoline (JAN/USAN/INN); Cabergoline [USAN:BAN:INN]; Cabergolinum; Cabergolinum [Latin]; Dostinex; Dostinex (TN); FCE-21336; Galastop; Sogilen
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hyperprolactinemia [ICD11: 5A60.1] | Approved | [1] | |||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C26H37N5O2
|
|||||
| Canonical SMILES |
CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C
|
|||||
| InChI |
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
|
|||||
| InChIKey |
KORNTPPJEAJQIU-KJXAQDMKSA-N
|
|||||
| CAS Number |
CAS 81409-90-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 451.6 | Topological Polar Surface Area | 71.7 | ||
| Heavy Atom Count | 33 | Rotatable Bond Count | 8 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
3.4
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103771070
, 10387
, 104305757
, 117539013
, 118047283
, 12013713
, 126624984
, 126656189
, 126684133
, 134337565
, 135013805
, 135652674
, 135989394
, 137001464
, 142175117
, 144206142
, 14759961
, 14808642
, 152101006
, 160963596
, 162179026
, 163133315
, 164155372
, 164824353
, 170464667
, 175267048
, 176484246
, 179151225
, 184546096
, 196111573
, 223682255
, 223820795
, 226427091
, 252222293
, 252391240
, 34718715
, 46508571
, 48415679
, 49965419
, 53787199
, 57313654
, 75968790
, 7848050
, 7978840
, 8183775
, 85788035
, 92309005
, 92713133
, 92740959
, 93166933
|
|||||
| ChEBI ID |
CHEBI:3286
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Cabergoline was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol. 2012 Sep;167(3):327-35. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.